Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 8/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.31 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129694 | 0.87 | PLA2G2A (0.42) | ALDH1A1HPGDTLR2TACR1PLA2G2A | |
| SCHEMBL31069862 | 0.84 | USP2 (0.40) | ALDH1A1HPGDPLA2G2A | |
| SCHEMBL24305059 | 0.84 | USP2 (0.40) | ALDH1A1HPGDPLA2G2A | |
| SCHEMBL31069864 | 0.80 | FFAR1 (0.38) | TLR2MAOBTACR1FFAR1PLA2G2A | |
| SCHEMBL24304737 | 0.80 | PLA2G2A (0.33) | ALDH1A1HPGDTACR1PLA2G2APLA2G10 | |
| SCHEMBL25335623 | 0.79 | LPAR3 (0.58) | — | |
| SCHEMBL25335620 | 0.79 | LPAR3 (0.58) | — | |
| SCHEMBL25336811 | 0.74 | ALDH1A1 (0.35) | ALDH1A1HPGDMAOBTACR1FFAR1 | |
| SCHEMBL31069861 | 0.72 | USP2 (0.51) | ALDH1A1 | |
| SCHEMBL25333782 | 0.71 | ALDH1A1 (0.40) | ALDH1A1HPGDMAOBTACR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118591377-A | Antiviral prodrugs, intermediate and long acting formulations and methods | 加利福尼亚大学董事会 | 2024-09-03 | — | — | CN | disclosed |